Bio-Techne (NASDAQ: TECH) reported Q4 EPS of $1.34, $0.05 better than the analyst estimate of $1.29. Revenue for the quarter came in at $180.3 million versus the consensus estimate of $174.77 million.

• Fourth quarter organic revenue increased by 9% (15% reported) to $180.3 million. Full year organic revenues increased by 9% (14% reported) to $643.0 million.
• GAAP EPS was $1.07 versus $0.74 one year ago, an increase of 45% over the prior year. Full year GAAP EPS was $3.29 versus $2.03 one year ago, an increase of 62% over the prior year.
• Delivered a record adjusted earnings per share (EPS) of $1.34 for the quarter and $4.54 for the full year, representing increases of 23% and 22%, respectively, over the prior year.
• Cash Flow from Operations was a record $64.4 million for the quarter.
• Adjusted Operating Margin was 39.5% for the quarter and 37.1% for the full year, up 80 and 10 basis points, respectively, over the prior year.
• Excellent commercial execution with all major regions and life science end-markets experiencing double-digit growth.

"Our team delivered an exceptional quarter to top off a record year for our company," said Chuck Kummeth, President and Chief Executive Officer of Bio-Techne. "Not only did we achieve 9% organic growth for the quarter, but we did for the entire year as well. My congratulations to the entire global Bio-Techne team now totaling over 2100 strong."

Kummeth added, "We are well positioned in our end-markets and are accelerating in our momentum to innovate best-in-class products for our customers which include those in the fields of research, diagnostics and therapeutics. Our recent acquisitions of Quad Technologies and ExosomeDx give us even more runway into the growing and scalable markets of Cell Therapy and Cancer Diagnostics, markets that already know our brands for research reagents and tools."

Kummeth concluded, "Our Advanced Cell Diagnostics platform finished the year with over 30% organic growth and we expect more growth from this very exciting diagnostic technology. And very soon, we are hopeful that Medicare will approve reimbursement for ExoDx® Prostate IntelliScore (EPI), a urine-based test, to assist physicians in determining the need for a prostate biopsy in patients with an ambiguous PSA test result. Medicare approval will support a rapid adoption for this exciting and game changing technology platform that improves patient care."

For earnings history and earnings-related data on Bio-Techne (TECH) click here.